Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Recursion Pharmaceuticals Inc Cl A (RXRX)

Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,728,445
  • Shares Outstanding, K 286,641
  • Annual Sales, $ 44,580 K
  • Annual Income, $ -328,070 K
  • EBIT $ -394 M
  • EBITDA $ -370 M
  • 60-Month Beta 0.85
  • Price/Sales 39.16
  • Price/Cash Flow N/A
  • Price/Book 3.32

Options Overview Details

View History
  • Implied Volatility 112.96% ( -1.05%)
  • Historical Volatility 112.34%
  • IV Percentile 92%
  • IV Rank 32.57%
  • IV High 206.11% on 11/29/24
  • IV Low 67.98% on 09/24/24
  • Put/Call Vol Ratio 0.52
  • Today's Volume 16,150
  • Volume Avg (30-Day) 21,722
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 238,848
  • Open Int (30-Day) 206,583

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.42
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.60 +7.68%
on 11/22/24
9.55 -36.86%
on 12/09/24
-0.01 (-0.17%)
since 11/20/24
3-Month
5.60 +7.68%
on 11/22/24
9.55 -36.86%
on 12/09/24
-0.77 (-11.32%)
since 09/20/24
52-Week
5.60 +7.68%
on 11/22/24
15.74 -61.69%
on 02/27/24
-3.43 (-36.26%)
since 12/20/23

Most Recent Stories

More News
Is Recursion Pharmaceuticals Stock a Millionaire Maker?

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power...

NVDA : 134.70 (+3.08%)
RXRX : 6.03 (-0.99%)
1 Artificial Intelligence (AI) Stock That Could Soar in 2025

The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025? It's hard to say, but whether or not it does, specific AI-focused...

RXRX : 6.03 (-0.99%)
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

RXRX : 6.03 (-0.99%)
Industry Survey Reveals Overwhelming Support for AI-Powered Healthcare

Issued on behalf of Avant Technologies Inc. VANCOUVER – USA News Group News Commentary – The healthcare sector is undergoing a profound transformation, propelled by the rapid evolution of artificial...

TWST : 47.94 (+9.90%)
AVAI : 0.5600 (+1.80%)
ABSI : 2.99 (+2.40%)
RXRX : 6.03 (-0.99%)
MDAI : 1.8900 (+0.53%)
RHHBY : 34.5000 (+0.76%)
Recursion Reports Promising Phase 1/2 Data for REC-617, a CDK7 Inhibitor, in Advanced Solid Tumors

REC-617 shows promising results in advanced solid tumors, with confirmed response in ovarian cancer and plans for further studies.Quiver AI SummaryRecursion announced promising initial data from its Phase...

RXRX : 6.03 (-0.99%)
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

RXRX : 6.03 (-0.99%)
An Investor's Guide to the Artificial Intelligence (AI) Value Chain

The artificial intelligence (AI) revolution extends far beyond chatbots and automation to fundamentally restructure information processing, decision-making, and infrastructure development. According to...

PATH : 13.25 (+4.00%)
GOOGL : 191.41 (+1.54%)
GTLB : 59.83 (+7.49%)
FROG : 30.86 (+0.98%)
MDB : 245.63 (+0.26%)
BOTZ : 32.29 (+1.54%)
TSLA : 421.06 (-3.46%)
AMD : 119.21 (+0.28%)
AUR : 7.19 (+0.14%)
META : 585.25 (-1.73%)
CEG : 227.02 (+0.82%)
SNOW : 166.29 (+1.27%)
Insider Sale: Chief Executive Officer of $RXRX (RXRX) Sells 20,000 Shares

Christopher Gibson, the Chief Executive Officer of $RXRX ($RXRX), sold 20,000 shares of the company on 12-05-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

RXRX : 6.03 (-0.99%)
The Future of Medicine: How AI Is Transforming Healthcare and Stock Markets

Issued on behalf of Avant Technologies Inc. VANCOUVER – USA News Group News Commentary – Artificial intelligence (AI) is rapidly reshaping the healthcare landscape, with experts suggesting...

AVAI : 0.5600 (+1.80%)
SYK : 364.60 (+2.09%)
RXRX : 6.03 (-0.99%)
RHHBY : 34.5000 (+0.76%)
TEM : 35.54 (+7.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering. Recursion Pharmaceuticals Inc. is based in SALT LAKE CITY.

See More

Key Turning Points

3rd Resistance Point 6.45
2nd Resistance Point 6.32
1st Resistance Point 6.18
Last Price 6.03
1st Support Level 5.91
2nd Support Level 5.78
3rd Support Level 5.64

See More

52-Week High 15.74
Fibonacci 61.8% 11.87
Fibonacci 50% 10.67
Fibonacci 38.2% 9.47
Last Price 6.03
52-Week Low 5.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar